Freshfields Bruckhaus Deringer is representing Johnson & Johnson in the transaction, and Fenwick & West is representing Shockwave Medical. Johnson & Johnson (NYSE: JNJ) and Shockwave Medical,...
Johnson & Johnson’s $13.1 Billion Acquisition of Shockwave Medical
Vertex Pharmaceuticals’ Acquisition of Alpine Immune Sciences
Skadden advised Vertex Pharmaceuticals Incorporated, while Fenwick & West advised Alpine in the transaction. Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc. have entered into a definitive...
EditCo Bio and Telegraph Hill Partners’ Acquisition of Synthego’s Engineered Cell Solutions Business
Fenwick & West represented Synthego in the transaction. EditCo Bio, Inc. announced that it has launched its business with the acquisition of Synthego’s engineered cell solutions...
Atara Biotherapeutics’ Partnership with Pierre Fabre Laboratories
Fenwick & West represented Atara Biotherapeutics, Inc. in the transaction. Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced it has entered into an expanded partnership with Pierre Fabre...
Standard BioTools’ Merger with SomaLogic
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised Standard BioTools Inc. on the transaction, and Fenwick & West advised SomaLogic, Inc. Standard BioTools Inc. (Nasdaq: LAB) and SomaLogic (Nasdaq:...
Pacific Biosciences’ Acquisition of Apton Biosystems
Wilson Sonsini Goodrich & Rosati is representing Pacific Biosciences, and Fenwick & West is representing Apton Biosystems in the transaction. 8Pacific Biosciences of California (NASDAQ: PACB) (PacBio) announced...
Recludix Pharma’s Collaboration with Sanofi
Fenwick & West represented Recludix Pharma in the deal. Recludix Pharma announced that it has entered into a strategic collaboration with Sanofi (NASDAQ: SNY) to develop and...
Novartis AG’s Acquisition of Chinook Therapeutics
Fenwick & West LLP represented Chinook Therapeutics, Inc. on the transaction, while Hogan Lovells US LLP represented Novartis AG. Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company, announced...
Shockwave Medical’s Pending Acquisition of Neovasc
Fenwick advised Shockwave Medical, Inc. on the deal. Shockwave Medical, Inc. (NASDAQ: SWAV), a medical device company focused on the development of Intravascular Lithotripsy (IVL) to...
Belharra Therapeutics’ Multi-year Collaboration with Genentech
Fenwick represented Belharra Therapeutics on the deal. Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, announced its multi-year collaboration with...
Sutro Biopharma’s Option Grant Agreement with Vaxcyte
Fenwick represented Sutro Biopharma on the deal. Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), announced its option grant...
SyntheX’s Research Collaboration with Bristol Myers Squibb
Fenwick represented SyntheX on the deal. SyntheX, a biotechnology company innovating next-generation functional drug discovery engines, announced its research collaboration and license agreement with Bristol Myers...